Takeda's AI-Designed Psoriasis Pill Beats BMY's Sotyktu, Pressuring Growth Portfolio

What happened

Takeda announced that its experimental once-daily psoriasis pill, developed with AI, outperformed Bristol Myers Squibb's approved drug Sotyktu in a late-stage head-to-head trial. This is a direct competitive threat to Sotyktu, which was already a relatively weak performer in BMY's Growth Portfolio, with only +4% sales growth in Q4 2025. The news raises questions about Sotyktu's long-term market potential and adds to the list of pipeline and commercial risks that BMY must manage during its portfolio transition. The result also highlights the increasing role of AI in drug discovery, potentially accelerating competitive pressure on traditional development approaches. While Sotyktu is not a major revenue driver today, its failure to gain traction and now a superior competitor emerging undermines the narrative that the Growth Portfolio can reliably offset Legacy Portfolio declines.

Implication

The Takeda result is a negative signal for BMY's immunology franchise and its ability to build new blockbusters from existing pipeline. While Sotyktu's absolute revenue contribution is small, the symbolic damage is meaningful: it shows that even recent launches can be leapfrogged by AI-accelerated competitors. Investors should monitor BMY's next earnings call for management's commentary on Sotyktu's competitive position and any planned lifecycle management. Over the medium term, this may increase the urgency for BMY to acquire or partner for later-stage assets to fill the pipeline gap.

Thesis delta

The thesis that BMY's Growth Portfolio can organically offset Legacy declines suffers a blow as a key recent launch (Sotyktu) is outclassed by a competitor. The bear case gains weight: portfolio transition may be slower and more costly, increasing the risk that 2026 guidance is not achieved. The bull case relying on Growth Portfolio acceleration is weakened.